Interpreting FDA’s New Guidance Document on Risk-based Monitoring

This webinar will train you on interpreting FDA's new guidance document on risk-based monitoring. It will include a case study demonstration on how any biopharmaceutical, medical device, and CRO could leverage the applications of breakthrough techniques to implement risk-based monitoring.

Why Should You Attend:

The drastic changes in the global macroeconomic environment is forcing biopharmaceutical, medical device and CRO enterprises to find new ways to operate more productively, strategically and cost effectively in today's economy.

Areas Covered in the Seminar:

• Global macroeconomic challenges & their effects on clinical trials.
• Interpretation of FDA's new guidance document on risk-based monitoring.
• Case study on risk-based monitoring.
• ICH/GCP in the new economy.
• Implementation of breakthrough tools to save costs, improve productivity, optimize monitoring operations and enhance clinical trial operational strategy.
• Efficiently improving clinical trial quality through risk-based monitoring.

Who Will Benefit:

• Clinical Quality Directors, Managers & Associates
• QA Directors, Managers & Associates
• Compliance VPs, Directors, Managers & Associates
• Clinical Operations Directors, Managers & Associates
• Clinical Research Directors, Managers & Associates